conference reports
Phase 2 trial of high-dose chemotherapy in patients with disseminated germ-cell tumours
Thursday, 2 July 2009- High-dose chemotherapy (HDCT) using the etoposide-carboplatin ± ifosfamide regimen is able to circumvent resistance in germ-cell tumour (GCT) patients (pts), even when used as third-line or later therapy...
Edited by: JV
BEP for CS1 non-seminoma: revising recommendations
Wednesday, 1 July 2009- In clinical stage I testicular cancer, one cycle of polychemotherapy (BEP) is as efficient as the currently accepted norm of two cycles of the same treatment, was one of the key messages at the 4th...
By Evgenia Starkova
Open versus laparoscopic RPLND in stage 1 nonseminomatous germ-cell tumours
Friday, 26 June 2009- Recurrence and complication rates in open and laparoscopic retroperitoneal lymph node dissection (RPLND) were examined by a group of Italian researchers. They presented their findings at the recent ASCO...
Edited by: JV
Complications of postchemotherapy residual tumour resection in testicular cancer patients
Friday, 29 May 2009- Residual tumour resection (RTR) is mandatory in all patients with advanced germ cell tumours and visible residual disease after chemotherapy. Full bilateral RTR is the proposed standard of care. However, in...
Edited by: JV
Swedish study shows long-term impaired language and decreased well-being among testis cancer survivors treated with chemotherapy
Tuesday, 14 April 2009- A group of Swedish researchers examined the cognitive function among testicular cancer patients who received chemotherapy compared to those who received no chemotherapy, and their study showed that these...
Edited by: JV
Chemo and radiotherapy sequels for testis cancer
Wednesday, 1 April 2009 - Today more than 90% of young men with newly diagnosed testicular cancer can expect a five-year survival. Epidemiological and clinical research has, however, shown that testicular cancer survivors...
By Dr. Sophie Fossa
Incidence of testicular cancer in the US, 1999-2004
Tuesday, 10 March 2009- Testicular cancer is the leading cancer diagnosed in men aged 20-39 years. To characterise the current incidence, demographics, and tumor characteristics of testicular cancer in the US, a group of...
Edited by: JV
Carboplatin as management option for stage 1 seminoma
Monday, 26 January 2009- One cycle of carboplatin can be recommended as an alternative to radiotherapy and surveillance for stage 1 seminoma, according to Prof. Günter Janetschek (Austria) during the recent 6th ESOU Meeting...
By Joel Vega
UK study shows carboplatin more ‘effective’ in testis cancer patients
Monday, 6 October 2008- Patients with an early and common form of testicular cancer respond better with a single chemotherapy treatment using carboplatin compared with radiotherapy which is known to have more debilitating...
Source: NCRI/News Agencies
Master Class with Weill Mediacl College of Cornell University from 20 to 26 July in Salzburg, Austria
Tuesday, 22 July 2008 - The master class of the European School of Urology in association with Weill Medical College of Cornell University is organised in Schloss Arenberg in Salzburg, Austria and started on Sunday 20 July. Young...
By: Lindy Brouwer
